Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Synergistic repression of thyroid hyperplasia by cyclin C and Pten.

Jezek J, Wang K, Yan R, Di Cristofano A, Cooper KF, Strich R.

J Cell Sci. 2019 Aug 15;132(16). pii: jcs230029. doi: 10.1242/jcs.230029.

PMID:
31331961
2.

PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.

Wong K, Di Cristofano F, Ranieri M, De Martino D, Di Cristofano A.

Endocr Relat Cancer. 2019 Apr 1;26(4):425-436. doi: 10.1530/ERC-19-0011. Epub 2019 Jan 1.

PMID:
30699064
3.

PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.

De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A.

Cancer Lett. 2018 Dec 28;439:56-65. doi: 10.1016/j.canlet.2018.09.024. Epub 2018 Sep 19.

PMID:
30243708
4.

SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.

Orlacchio A, Ranieri M, Brave M, Arciuch VA, Forde T, De Martino D, Anderson KE, Hawkins P, Di Cristofano A.

Cancer Res. 2017 Dec 15;77(24):6914-6926. doi: 10.1158/0008-5472.CAN-17-2105. Epub 2017 Oct 20.

5.

SGK1: The Dark Side of PI3K Signaling.

Di Cristofano A.

Curr Top Dev Biol. 2017;123:49-71. doi: 10.1016/bs.ctdb.2016.11.006. Epub 2016 Dec 15. Review.

6.

Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis.

Champa D, Orlacchio A, Patel B, Ranieri M, Shemetov AA, Verkhusha VV, Cuervo AM, Di Cristofano A.

Oncotarget. 2016 Jun 7;7(23):34453-71. doi: 10.18632/oncotarget.9121.

7.

MCM5 as a target of BET inhibitors in thyroid cancer cells.

Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppin C, Filetti S, Durante C, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G.

Endocr Relat Cancer. 2016 Apr;23(4):335-47. doi: 10.1530/ERC-15-0322. Epub 2016 Feb 24.

8.

Modeling anaplastic thyroid carcinoma in the mouse.

Champa D, Di Cristofano A.

Horm Cancer. 2015 Feb;6(1):37-44. doi: 10.1007/s12672-014-0208-8. Epub 2014 Nov 25. Review.

9.

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Champa D, Russo MA, Liao XH, Refetoff S, Ghossein RA, Di Cristofano A.

Endocr Relat Cancer. 2014 Oct;21(5):755-67. doi: 10.1530/ERC-14-0268. Epub 2014 Jul 10.

10.

Obesity and thyroid cancer: is leptin the (only) link?

Di Cristofano A.

Endocrinology. 2013 Aug;154(8):2567-9. doi: 10.1210/en.2013-1567. No abstract available.

11.

Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells.

Antico Arciuch VG, Russo MA, Kang KS, Di Cristofano A.

Cancer Res. 2013 Sep 1;73(17):5459-72. doi: 10.1158/0008-5472.CAN-13-1429. Epub 2013 Jun 24.

12.

Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.

Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G.

Endocrinology. 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013-1028. Epub 2013 Jun 10.

13.

Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development.

Danescu A, Herrero Gonzalez S, Di Cristofano A, Mai S, Hombach-Klonisch S.

Genes Chromosomes Cancer. 2013 Aug;52(8):716-32. doi: 10.1002/gcc.22067. Epub 2013 Apr 30.

14.

The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Russo MA, Kang KS, Di Cristofano A.

Thyroid. 2013 Oct;23(10):1284-93. doi: 10.1089/thy.2013.0037. Epub 2013 Jul 25.

15.

New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.

Herrero-Gonzalez S, Di Cristofano A.

Cancer Discov. 2011 Jul;1(2):106-7. doi: 10.1158/2159-8290.CD-11-0116.

16.

Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.

Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C, Di Cristofano A.

Oncotarget. 2011 Dec;2(12):1109-26.

17.

Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain-dependent manner.

Tiozzo C, Danopoulos S, Lavarreda-Pearce M, Baptista S, Varimezova R, Al Alam D, Warburton D, Virender R, De Langhe S, Di Cristofano A, Bellusci S, Minoo P.

Endocr Relat Cancer. 2012 Apr 10;19(2):111-122. doi: 10.1530/ERC-10-0327. Print 2012 Apr. Erratum in: Endocr Relat Cancer. 2013 Apr;20(2):X1. Virender, Rehan [corrected to Rehan, Virender].

18.

Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research.

Dima M, Miller KA, Antico-Arciuch VG, Di Cristofano A.

Thyroid. 2011 Sep;21(9):1001-7. doi: 10.1089/thy.2011.0030. Epub 2011 Jul 18.

19.

Mouse models of follicular and papillary thyroid cancer progression.

Russo MA, Antico Arciuch VG, Di Cristofano A.

Front Endocrinol (Lausanne). 2012 Jan 10;2:119. doi: 10.3389/fendo.2011.00119. eCollection 2011.

20.

Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A.

Oncogene. 2010 Oct 21;29(42):5678-86. doi: 10.1038/onc.2010.308. Epub 2010 Aug 2.

21.

GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Altomare DA, Zhang L, Deng J, Di Cristofano A, Klein-Szanto AJ, Kumar R, Testa JR.

Clin Cancer Res. 2010 Jan 15;16(2):486-96. doi: 10.1158/1078-0432.CCR-09-1026.

22.

Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A.

Cancer Res. 2009 Apr 15;69(8):3689-94. doi: 10.1158/0008-5472.CAN-09-0024. Epub 2009 Apr 7.

23.

Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.

Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B.

Cancer Res. 2009 Jan 15;69(2):678-86. doi: 10.1158/0008-5472.CAN-08-3980.

24.

A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.

Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z, Gao Q, Jhanwar SC, Di Cristofano A, Wiest DL, Knepper JE, Testa JR.

Cancer Res. 2008 Mar 1;68(5):1296-302. doi: 10.1158/0008-5472.CAN-07-3218.

25.

Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium.

Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A.

Cancer Res. 2008 Jan 15;68(2):444-9. doi: 10.1158/0008-5472.CAN-07-3030.

26.

Endometrial carcinoma.

Di Cristofano A, Ellenson LH.

Annu Rev Pathol. 2007;2:57-85. Review.

PMID:
18039093
27.
28.
29.

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N.

Genes Dev. 2006 Jun 15;20(12):1569-74.

30.
31.

Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.

Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, Di Cristofano A.

Cancer Res. 2006 Apr 1;66(7):3375-80.

32.

Class reunion: PTEN joins the nuclear crew.

Lian Z, Di Cristofano A.

Oncogene. 2005 Nov 14;24(50):7394-400. Review.

PMID:
16288286
33.

Somatic acquisition and signaling of TGFBR1*6A in cancer.

Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di Cristofano A, Hampel H, Nilsson I, von Heijne G, Fodde R, Murty VV, de la Chapelle A, Weghorst CM.

JAMA. 2005 Oct 5;294(13):1634-46.

PMID:
16204663
34.

Activation of AKT kinases in cancer: implications for therapeutic targeting.

Bellacosa A, Kumar CC, Di Cristofano A, Testa JR.

Adv Cancer Res. 2005;94:29-86. Review.

PMID:
16095999
35.
36.

Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.

Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR.

Oncogene. 2005 May 19;24(22):3574-82.

PMID:
15806173
37.

Role of Dok-1 and Dok-2 in leukemia suppression.

Niki M, Di Cristofano A, Zhao M, Honda H, Hirai H, Van Aelst L, Cordon-Cardo C, Pandolfi PP.

J Exp Med. 2004 Dec 20;200(12):1689-95.

38.
39.

Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain.

Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, Vezzani A, Ottolenghi S, Pandolfi PP, Sala M, DeBiasi S, Nicolis SK.

Development. 2004 Aug;131(15):3805-19. Epub 2004 Jul 7.

40.

Pten dose dictates cancer progression in the prostate.

Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP.

PLoS Biol. 2003 Dec;1(3):E59. Epub 2003 Oct 27.

41.

Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N.

Mol Cell Biol. 2002 Nov;22(22):7831-41.

42.

The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells.

Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, Cordon-Cardo C, Mao S, Pandolfi PP, Nimer SD.

Immunity. 2002 Oct;17(4):437-49.

43.

PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.

Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, Evers BM.

Gastroenterology. 2002 Oct;123(4):1163-78.

PMID:
12360479
44.

PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation.

Li L, Liu F, Salmonsen RA, Turner TK, Litofsky NS, Di Cristofano A, Pandolfi PP, Jones SN, Recht LD, Ross AH.

Mol Cell Neurosci. 2002 May;20(1):21-9.

PMID:
12056837
45.

Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors.

Parisi T, Pollice A, Di Cristofano A, CalabrĂ² V, La Mantia G.

Biochem Biophys Res Commun. 2002 Mar 15;291(5):1138-45.

PMID:
11883935
46.

p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).

Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L, Pandolfi PP.

J Exp Med. 2001 Aug 6;194(3):275-84.

47.
48.

Chromosomal distribution, localization and expression of the human endogenous retrovirus ERV9.

Svensson AC, Raudsepp T, Larsson C, Di Cristofano A, Chowdhary B, La Mantia G, Rask L, Andersson G.

Cytogenet Cell Genet. 2001;92(1-2):89-96.

PMID:
11306803
49.

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.

Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP.

Nat Genet. 2001 Feb;27(2):222-4.

PMID:
11175795
50.

Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice.

Arpaia E, Benveniste P, Di Cristofano A, Gu Y, Dalal I, Kelly S, Hershfield M, Pandolfi PP, Roifman CM, Cohen A.

J Exp Med. 2000 Jun 19;191(12):2197-208.

Supplemental Content

Loading ...
Support Center